USPH Net Tangible Assets from 2010 to 2026
| USPH Stock | USD 76.83 -0.59 -0.76% |
Net Tangible Assets | First Reported 2011-06-30 | Previous Quarter 39.7 M | Current Value -143 M | Quarterly Volatility 75 M |
Macro event markers
Financial statement trends for US Physicalrapy provide structured context on operating performance and capital structure. Track Interest Expense of 9.9 M, Total Revenue of 820 M or Gross Profit of 165.2 M and ratios such as Price To Sales Ratio of 2.93, Dividend Yield of 0.0198 or PTB Ratio of 4.6 to align performance context with US Physicalrapy Valuation and Volatility.
USPH | Net Tangible Assets | Build AI portfolio with USPH Stock |
The Net Tangible Assets trend for US Physicalrapy offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether US Physicalrapy is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest US Physicalrapy's Net Tangible Assets Growth Pattern
Below is the plot of the Net Tangible Assets of US Physicalrapy over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. US Physicalrapy's Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in US Physicalrapy's overall financial position and show how it may be relating to other accounts over time.
| Net Tangible Assets | 10 Years Trend |
|
Net Tangible Assets |
| Timeline |
USPH Net Tangible Assets Regression Statistics
| Arithmetic Mean | -101,598,504 | |
| Coefficient Of Variation | -125.04 | |
| Mean Deviation | 115,393,946 | |
| Median | -26,541,000 | |
| Standard Deviation | 127,039,172 | |
| Sample Variance | 16139T | |
| Range | 294.8M | |
| R-Value | -0.81 | |
| Mean Square Error | 5851.5T | |
| R-Squared | 0.66 | |
| Significance | 0.000074 | |
| Slope | -20,439,465 | |
| Total Sum of Squares | 258223.2T |
USPH Net Tangible Assets History
Stock Overview, Methodology & Data Sources
Physical Therapy, Inc., through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The company was founded in 1990 and is based in Houston, Texas. US Physical operates under Medical Care Facilities classification in the United States and is traded on New York Stock Exchange. It employs 3158 people. A high-level view of US Physicalrapy emphasizes earnings durability, balance-sheet flexibility, and competitive positioning. Current metrics include P/E of 34.35, P/B of 2.44, profit margin of 5.12%. US Physicalrapy has a market cap of 1.17 B, P/E of 34.35, ROE of 7.59%.
Methodology
Unless otherwise specified, financial data for US Physicalrapy is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. USPH (USA Stocks:USPH) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Inputs are aggregated from public filings and market reference sources and public institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Food & Drug Administration (FDA). Certain values may not reflect real-time changes. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
US Physicalrapy may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Ellen Johnson - Member of Macroaxis Editorial BoardCurrently Active Assets on Macroaxis
More Resources for USPH Stock Analysis
Reviewing US Physicalrapy commonly begins with financial statements and performance trends. Key ratios help frame profitability, efficiency, and growth context for US Physicalrapy Stock. Below are reports that help frame US Physicalrapy Stock in context:US Physicalrapy Correlation provides competitor comparison context for US Physicalrapy. The view adds relative comparison context. Learn how to buy and trade USPH Stock using our step-by-step How to Buy US Physicalrapy guide.Analysis related to US Physicalrapy should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Quarterly Earnings Growth 0.236 | Dividend Share 1.8 | Earnings Share 1.42 | Revenue Per Share | Quarterly Revenue Growth 0.125 |
Investors evaluate US Physicalrapy using market value and book value, each describing different facets of the business. US Physicalrapy's market capitalization is 1.17 B. A P/B ratio of 2.44 indicates the market values US Physicalrapy above its accounting book value. Enterprise value stands at 1.44 B. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
The concept of value for US Physicalrapy differs from its quoted price, since each reflects a different lens. For US Physicalrapy, key inputs include a P/E ratio of 34.35, a P/B ratio of 2.44, a profit margin of 5.12%, and ROE of 7.59%. By contrast, market price reflects the level where buyers and sellers transact.